CARD14变异相关皮肤病的分子机制与诊治进展

doi:10.12372/jcp.2026.25e1600

Abstract

Abstract:

In recent years, with advances in molecular biology and genetics, the CARD14 gene has been confirmed to be closely related to a variety of diseases. Patients typically develop symptoms shortly after birth, which severely impacts their health and quality of life. Due to the large clinical heterogeneity of this group of diseases and the difficulty in treatment, early identification and personalized intervention have significant clinical significance. This article systematically expounds the molecular mechanism, clinical phenotype spectrum and the latest progress of targeted therapy of CARD14-related skin diseases, aiming to provide theoretical basis and clinical reference for the precise diagnosis and treatment of such diseases.

Key words: CARD14, molecular mechanism, child

CLC Number:

ZHAO Xinrong, XU Zigang. Molecular mechanisms, diagnosis, and treatment of skin disorders associated with CARD14 mutations[J].Journal of Clinical Pediatrics, 2026, 44(5): 399-404.

References 38

[1]	Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14[J]. Am J Hum Genet, 2012, 90(5): 784-795. doi: 10.1016/j.ajhg.2012.03.012 pmid: 22521418
[2]	Peled A, Sarig O, Sun G, et al. Loss-of-function mutations in caspase recruitment domain-containing protein 14 (CARD14) are associated with a severe variant of atopic dermatitis[J]. J Allergy Clin Immunol, 2019, 143(1): 173-181. doi: S0091-6749(18)31348-4 pmid: 30248356
[3]	Takeichi T, Kobayashi A, Ogawa E, et al. Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation[J]. Br J Dermatol, 2017, 177(4): e133-e135.
[4]	Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris[J]. J Am Acad Dermatol, 2018, 79(3): 487-494. doi: S0190-9622(18)30319-0 pmid: 29477734
[5]	Zerillo L, Zotti T, Tutela A, et al. The CARD14sh-BCL10-MALT1 complex regulates MAVS-mediated antiviral response in keratinocytes[J]. Proc Natl Acad Sci U S A, 2025, 122(24): e2500711122. doi: 10.1073/pnas.2500711122
[6]	Afonina IS, Van Nuffel E, Baudelet G, et al. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes[J]. EMBO Rep, 2016, 17(6): 914-927. doi: 10.15252/embr.201642109 pmid: 27113748
[7]	DeVore SB, Khurana Hershey GK. The role of the CBM complex in allergic inflammation and disease[J]. J Allergy Clin Immunol, 2022, 150(5): 1011-1030. doi: 10.1016/j.jaci.2022.06.023 pmid: 35981904
[8]	Ruland J, Hartjes L. CARD-BCL-10-MALT1 signalling in protective and pathological immunity[J]. Nat Rev Immunol, 2019, 19(2): 118-134. doi: 10.1038/s41577-018-0087-2 pmid: 30467369
[9]	Zhang S, Wang M, Wang C, et al. Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation through the IL-23/T17 Axis in a MALT1-Dependent Manner[J]. J Immunol, 2021, 206(4): 839-848. doi: 10.4049/jimmunol.2001031 pmid: 33419765
[10]	Wang M, Zhang S, Zheng G, et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A[J]. Immunity, 2018, 49(1): 66-79. doi: S1074-7613(18)30250-4 pmid: 29980436
[11]	Sundberg JP, Pratt CH, Silva KA, et al. Gain of function p.E138A alteration in Card14 leads to psoriasiform skin inflammation and implicates genetic modifiers in disease severity[J]. Exp Mol Pathol, 2019, 110: 104286. doi: 10.1016/j.yexmp.2019.104286
[12]	Mellett M, Meier B, Mohanan D, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo[J]. J Invest Dermatol, 2018, 138(9): 2010-2023. doi: S0022-202X(18)31874-8 pmid: 29689250
[13]	Yoshikawa T, Takeichi T, Hirabayashi T, et al. Hyperactivation of the IL-17 axis and IL-36 signaling in Card14-mutant pityriasis rubra pilaris mouse model[J]. J Invest Dermatol, 2025, 145(2): 427-432. doi: 10.1016/j.jid.2024.04.036
[14]	Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis[J]. Am J Hum Genet, 2012, 90(5): 796-808. doi: 10.1016/j.ajhg.2012.03.013 pmid: 22521419
[15]	Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis[J]. Lancet, 2007, 370(9583): 263-271. doi: S0140-6736(07)61128-3 pmid: 17658397
[16]	Lopez-Sanchez C, Falla LM, Roe-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis[J]. J Dermatol, 2021, 48(6): 907-910. doi: 10.1111/jde.v48.6
[17]	Akiyama M. Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets[J]. J Dermatol Sci, 2022, 105(1): 11-17. doi: 10.1016/j.jdermsci.2021.11.009
[18]	Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis (PPP) in the Chinese Han population[J]. Eur J Dermatol, 2019, 29(1): 99-100. doi: 10.1684/ejd.2018.3457 pmid: 30998217
[19]	Tobita R, Egusa C, Maeda T, et al. A novel CARD14 variant, homozygous c.526G>C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis[J]. Clin Exp Dermatol, 2019, 44(6): 694-696. doi: 10.1111/ced.13926 pmid: 30723930
[20]	Shajil C, Sathishkumar D, Kumar S, et al. Homozygous CARD14 variant presenting as infantile erythroderma[J]. BMJ Case Rep, 2024, 17(1): e254090. doi: 10.1136/bcr-2022-254090
[21]	Nielsen RM, Gram SB, Bygum A. Identification of a pathogenic CARD14 mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy[J]. BMJ Case Rep, 2021, 14(1): e235287. doi: 10.1136/bcr-2020-235287
[22]	Takeichi T, Sugiura K, Nomura T, et al. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 mutations[J]. JAMA Dermatol, 2017, 153(1): 66-70. doi: 10.1001/jamadermatol.2016.3601 pmid: 27760266
[23]	Atzmony L, Ugwu N, Hamilton C, et al. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders[J]. Pediatr Dermatol, 2022, 39(6): 903-907. doi: 10.1111/pde.15094 pmid: 35853659
[24]	Riachi M, Polubothu S, Stadnik P, et al. Molecular genetic dissection of inflammatory linear verrucous epidermal naevus leads to successful targeted therapy[J]. J Invest Dermatol, 2021, 141(12): 2979-2983. doi: 10.1016/j.jid.2021.02.765 pmid: 34116062
[25]	Zhao X, Miao C, Xiang X, et al. Effect of secukinumab on inflammatory linear verrucous epidermal naevus with a somatic mutation in CARD14[J]. Clin Exp Dermatol, 2024, 49(6): 631-633. doi: 10.1093/ced/llae047
[26]	Ring NG, Craiglow BG, Panse G, et al. Histopathologic findings characteristic of CARD14-associated papulos-quamous eruption[J]. J Cutan Pathol, 2020, 47(5): 425-430. doi: 10.1111/cup.13633 pmid: 31849081
[27]	Kiszewski AE, De Almeida HL Jr. Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child[J]. Dermatol Ther, 2022, 35(12): e15939.
[28]	Nogueira M, Reis J, Abreu M, et al. A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab[J]. Pediatr Dermatol, 2023, 40(6): 1104-1106. doi: 10.1111/pde.15336 pmid: 37219506
[29]	Frare CP, Blumstein AJ, Paller AS, et al. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature[J]. Pediatr Dermatol, 2021, 38(5): 1237-1242. doi: 10.1111/pde.14779 pmid: 34448248
[30]	Chessa MA, Rossi AN, Baracca MF, et al. CARD14-associated papulosquamous eruption flare-up after SARS-CoV-2 infection in a child: secukinumab a safe and effective treatment[J]. Int J Dermatol, 2023, 62(10): 1304-1306. doi: 10.1111/ijd.16790 pmid: 37421198
[31]	Dai S, Zhang S, Wang C, et al. CARD14 Missense variant underlying CARD14-associated papulosquamous eruption with beneficial response to secukinumab[J]. JID Innov, 2023, 3(2): 100174. doi: 10.1016/j.xjidi.2022.100174
[32]	Klein B, Treudler R, Dumann K, et al. Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody[J]. Br J Dermatol, 2022, 187(3): 419-422. doi: 10.1111/bjd.21229
[33]	Sawabe Y, Hayashi K, Kamata M, et al. Case of generalized pustular psoriasis with coexisting mutations in IL36RN and CARD14[J]. J Dermatol, 2019, 46(10): e368-e370.
[34]	Millak L, Hahn M, Fischer J, et al. Case Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with ixekizumab[J]. Front Med (Lausanne), 2025, 12: 1637045.
[35]	Gu C, Yang J. Risankizumab for the treatment of psoriasis[J]. Expert Rev Clin Pharmacol, 2019, 12(9): 851-857. doi: 10.1080/17512433.2019.1657829
[36]	Kolt-Kaminska M, Osinska A, Kaznowska E, et al. Successful treatment of pityriasis rubra pilaris with risankizumab in children[J]. Dermatol Ther (Heidelb), 2023, 13(10): 2431-2441. doi: 10.1007/s13555-023-01005-y
[37]	Thapar M, Patel M, Gordon K. Bimekizumab for the treatment of psoriasis[J]. Immunotherapy, 2024, 16(7): 431-446. doi: 10.2217/imt-2023-0240 pmid: 38506262
[38]	Rossel SVJ, Reich A, Baniel A, et al. Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption[J]. J Eur Acad Dermatol Venereol, 2025, 39(6):e485-e489.

Molecular mechanisms, diagnosis, and treatment of skin disorders associated with CARD14 mutations

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 38

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.